VKTX has experienced a notable decline in its stock price, dropping from around $80 to $30 within three months. The company's injectable and oral treatment VK-2735 is viewed as having an increasingly attractive profile, particularly as competitors face challenges with tolerability. Key near-term catalysts for VKTX include advancement into Phase 3 trials and clarity on commercial manufacturing. Despite the stock's recent downturn, some investors believe that the fundamentals remain intact. The stock previously reached a high of over $90 following positive oral data updates, marking a 2500% gain from its earlier price of approximately $3.80. However, the stock has since lost substantial value, with a reported decrease of 63% since the release of data post-FDA news. The overall sentiment in the biotech sector remains cautious as several companies, including VKTX, have seen significant stock price declines recently.